In short
Regorafenib is an oral medication being studied in clinical trials for various types of cancer, including colorectal cancer, liver cancer, and bone tumors. This article summarizes key information about ongoing clinical trials investigating regorafenib's effectiveness, safety, and potential biomarkers in cancer patients who have not responded to standard treatments.
At a glance
- Cancer Types Studied
- Colorectal cancer, hepatocellular carcinoma, angiosarcoma, osteosarcoma, Ewing sarcoma
- Common Dosing
- 160 mg orally daily for 3 weeks, followed by 1 week off (28-day cycle)
- Key Outcomes Measured
- Overall survival, progression-free survival, response rates, safety/tolerability
- Common Side Effects
- Fatigue, hand-foot skin reaction, diarrhea, liver function abnormalities
- Patient Population
- Advanced cancer patients who have progressed after standard treatments
- Biomarker Research
- Some trials exploring genetic mutations, protein levels, and other biomarkers
- Combination Studies
- Investigations of regorafenib with other drugs (e.g., XELOX chemotherapy)
What is Regorafenib?
Regorafenib is a medication used to treat various types of cancer. It's also known by its brand name Stivarga. Regorafenib belongs to a class of drugs called multikinase inhibitors, which means it works by blocking several proteins that help cancer cells grow and spread.
What Conditions Does Regorafenib Treat?
Regorafenib has been approved and is being studied for several types of cancer:
- Colorectal Cancer: It's used to treat metastatic colorectal cancer (cancer that has spread from the colon or rectum to other parts of the body) in patients who have already tried other standard treatments.
- Gastrointestinal Stromal Tumors (GIST): Regorafenib is approved for patients with GIST that has progressed after treatment with other therapies.
- Hepatocellular Carcinoma (HCC): This is a type of liver cancer. Regorafenib is being studied as a second-line treatment for patients with unresectable HCC (liver cancer that cannot be surgically removed).
- Glioblastoma: Research is ongoing to evaluate regorafenib's effectiveness in treating this aggressive type of brain cancer.
- Esophageal and Gastric Cancer: Studies are investigating the use of regorafenib in combination with other treatments for these types of cancers.
How Does Regorafenib Work?
Regorafenib works by targeting multiple proteins involved in cancer growth and progression. Specifically, it inhibits:
- Angiogenesis: This is the process by which tumors create new blood vessels to supply themselves with nutrients. Regorafenib blocks proteins called VEGFRs (Vascular Endothelial Growth Factor Receptors) that are crucial for this process.
- Oncogenic signaling: The drug also inhibits proteins involved in cancer cell growth and survival, such as RAF and BRAF.
- Tumor microenvironment: Regorafenib affects proteins that help create a favorable environment for tumor growth.
By targeting these multiple pathways, regorafenib aims to slow down or stop cancer growth and spread.
Dosage and Administration
Regorafenib is typically taken orally (by mouth) in the form of tablets. The standard dosage is often 160 mg once daily, but this can vary depending on the specific condition and individual patient factors. Some important points about taking regorafenib:
- It's usually taken for 3 weeks, followed by a 1-week break. This 4-week period is considered one treatment cycle.
- The medication should be taken with a light meal.
- Some studies are exploring different dosing schedules, such as starting at a lower dose and gradually increasing it to improve tolerability.
Always follow your doctor's instructions regarding dosage and administration.
Side Effects and Safety
Like all medications, regorafenib can cause side effects. Some of the most common include:
- Fatigue
- Diarrhea
- Hand-foot skin reaction (redness, swelling, and pain on the palms of hands and soles of feet)
- Loss of appetite
- High blood pressure
These side effects can sometimes be severe, particularly in women and patients with lower body weight. Your healthcare team will monitor you closely and may adjust your dose if needed. It's important to report any side effects to your doctor promptly.
Ongoing Research and Future Potential
Researchers are continually studying regorafenib to understand how to use it most effectively and safely. Some areas of ongoing research include:
- Combination therapies: Studies are looking at combining regorafenib with other treatments, such as immunotherapy drugs like sintilimab for liver cancer.
- New cancer types: Researchers are investigating regorafenib's potential in treating other types of cancer, such as meningioma (a type of brain tumor).
- Optimizing dosage: Studies are exploring ways to adjust the dosage based on factors like body composition to improve tolerability and effectiveness.
- Adjuvant therapy: Some research is looking at using regorafenib as an additional treatment after main cancer therapy to prevent recurrence.
These ongoing studies aim to expand our understanding of regorafenib and potentially broaden its use in cancer treatment.